

Our ref: FOI 999

14th April 2022

SOUTHERN HEALTH & SOCIAL CARE TRUST

FREEDOM OF INFORMATION RESPONSE 999

Q1. In the past 6 months (latest 6 months available) how many patients have received the following Immunoglobulin treatments (for any disease):

• Cutaquig	Nil
• Cuvitru	Nil
• Gammanorm	Nil
• Hizentra	<5
• Hyqvia	Nil
• Subgam	Nil
• Privigen	56
• Octagam	11
• Intratect	5
• Gamunex	<5
• Kiovig	Nil
• Panzyga	Nil
• Iqymune	Nil
• Gammalex	Nil

Part 2

Q2. In the past 6 months (latest 6 months available) how many patients have received the following treatments (for any disease):

• Berinert (Human C1-esterase inhibitor)	<5
• Cinryze (Human C1-esterase inhibitor)	Nil
• Firazyr (Icatibant injection)	Nil
• Orladeyo (Berotralstat)	Nil
• Ruconest (Recombinant Human C1-esterase inhibitor)	Nil
• Takhzyro (Lanadelumab)	Nil

Q3. In the past 2 years, how many patients have been diagnosed (primary and secondary) with Hereditary Angioedema (ICD-10 code D84.1)

Please see attached spreadsheet for inpatient finished consultant episodes for ICD- 10 code D84.1. We are unable to provide the number of patients diagnosed but can provide the number of patients that were admitted during this period that were coded with a diagnosis of Hereditary Angioedema.

Part 3

Q4. For the patients identified in Q3 above, how many patients have been treated (for any condition) in the past 6 months with the following drugs:

- **Danazol – <5 patient**
- Oxandralone Nil
- Stanozolol Nil

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net